Provided by Tiger Trade Technology Pte. Ltd.

IMMUNEONCO-B

3.710
0.000
Volume:1.31M
Turnover:5.01M
Market Cap:1.59B
PE:-6.00
High:3.930
Open:3.700
Low:3.700
Close:3.710
52wk High:16.800
52wk Low:2.800
Shares:429.00M
HK Float Shares:418.00M
Volume Ratio:1.41
T/O Rate:0.31%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.618
ROE:-40.11%
ROA:-16.24%
PB:2.18
PE(LYR):-6.00
PS:10.83

Loading ...

IMMUNEONCO-B (01541) Redeems HK$205 Million Shenwan Products and Subscribes to HK$212 Million Shenwan Hongyuan Wealth Management Products

Stock News
·
May 22

ImmuneOnco Biopharmaceuticals (Shanghai) Inc - to Subscribe for HK$212 Mln Shenwan Wealth Management Product on May 22, 2026

THOMSON REUTERS
·
May 22

ImmuneOnco Doses First Patient in IMM0306 Drug Trial; Shares Fall 3%

MT Newswires Live
·
May 20

IMMUNEONCO-B (01541) Achieves Milestone with First Patient Dosed in Phase II SLE Trial for IMM0306

Stock News
·
May 19

IMMUNEONCO-B Surges Over 6% in Late Trading as IND Application for IMM0306 in Primary Sjögren's Syndrome Gains Official Approval

Stock News
·
May 19

ImmuneOnco records stable share base in April 2026; public-float requirement fully met

Bulletin Express
·
May 07

ImmuneOnco Biopharmaceuticals announces annual general meeting notice

Reuters
·
Apr 30

ImmuneOnco Biopharmaceuticals收入倍增 2025年研发布局稳步扩张,全年亏损明显收窄

Bulletin Express
·
Apr 29

IMMUNEONCO-B Shares Climb Over 5% as Subsidiary Completes Patient Enrollment for IMC-003 Study

Stock News
·
Apr 22

IMMUNEONCO-B Soars Over 17% as Science Journal Validates CD47 Bispecific Antibody's Clinical Potential

Stock News
·
Apr 13

Stock Track | IMMUNEONCO-B Soars 5.15% in Intraday Trading on Phase III Clinical Trial Milestone

Stock Track
·
Mar 31

IMMUNEONCO-B (01541) Administers First Dose in Phase III Trial of IMM0306 for Relapsed/Refractory Follicular Lymphoma

Stock News
·
Mar 31

IMMUNEONCO-B Initiates Phase III Study: First Patient Dosed with Dual-Targeting Therapy IMM0306 for Relapsed/Refractory Follicular Lymphoma

Bulletin Express
·
Mar 30

ImmuneOnco doses first patient in Phase III IMM0306 trial for relapsed/refractory follicular lymphoma

Reuters
·
Mar 30

ImmuneOnco Biopharmaceuticals (SEHK:1541) Losses Narrow 23.6% Annually Challenging Bearish Narratives

Simply Wall St.
·
Mar 27

Instil Bio FY2025 net loss per share narrows 6.06% to $10.70; revenue was not reported

Reuters
·
Mar 27

BRIEF-Immuneonco Biopharmaceuticals Shanghai Inc Posts FY Loss Attributable RMB218.6 Million

Reuters
·
Mar 25

IMMUNEONCO-B Reports Fiscal Year Performance: Revenue Jumps 108.09% to 154 Million Yuan

Stock News
·
Mar 25

ImmuneOnco Posts FY-2025 Loss Narrowing to RMB219 Million; Revenue Doubles on Up-fronts and Milestones

Bulletin Express
·
Mar 25

ImmuneOnco Biopharmaceuticals Shanghai Inc - FY Loss Attributable RMB218.6 Mln

THOMSON REUTERS
·
Mar 25